We are live on ! Find out more
LGND icon

Ligand Pharmaceuticals
LGND

357 hedge funds and large institutions have $4.15B invested in Ligand Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 133 increasing their positions, 115 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 43

22% more call options, than puts

Call options by funds: $8.48M | Put options by funds: $6.95M

16% more repeat investments, than reductions

Existing positions increased: 133 | Existing positions reduced: 115

7% more capital invested

Capital invested by funds: $3.89B → $4.15B (+$264M)

2% more funds holding

Funds holding: 349 → 357 (+8)

0% more funds holding in top 10

Funds holding in top 10: 8 → 8 (0)

0.18% less ownership

Funds ownership: 104.47% → 104.29% (-0.18%)

Holders
357
Holders Change
+8
Holders Change %
+2.29%
% of All Funds
4.39%
Holding in Top 10
8
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
59
Increased
133
Reduced
115
Closed
43
Calls
$8.48M
Puts
$6.95M
Net Calls
+$1.54M
Net Calls Change
-$3.42M

Top Buyers

1
Invesco
Invesco
Georgia
+$60.8M
2
NCGI
Next Century Growth Investors
Minnesota
+$19M
3
Bessemer Group
Bessemer Group
New Jersey
+$16.7M
4
Franklin Resources
Franklin Resources
California
+$15.2M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$12.9M

Top Sellers

1
UBS AM
UBS AM
Illinois
-$29.8M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$21M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$18.9M
4
NAMI
Nomura Asset Management International
Pennsylvania
-$14M
5
Goldman Sachs
Goldman Sachs
New York
-$9.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
226
Ameritas Investment Partners
Nebraska
$318K – – –
CL
227
Choreo LLC
Illinois
$313K +$32.8K +166 +12%
SGK
228
Steigerwald Gordon & Koch
Virginia
$313K – – –
HIM
229
Hillsdale Investment Management
Ontario, Canada
$307K +$297K +1,500 +3,750%
SFS
230
Sowell Financial Services
Arkansas
$303K +$37.2K +188 +14%
GCM
231
Graham Capital Management
Connecticut
$301K +$298K +1,506 New
CIM
232
CIM Investment Management
Pennsylvania
$296K +$9.7K +49 +3%
Neuberger Berman Group
233
Neuberger Berman Group
New York
$292K +$37.8K +191 +15%
TRCT
234
Tower Research Capital (TRC)
New York
$283K +$131K +661 +87%
SG Americas Securities
235
SG Americas Securities
New York
$283K -$1.86M -9,401 -87%
Blackstone Inc
236
Blackstone Inc
New York
$282K +$279K +1,412 New
B
237
Bailard
California
$280K – – –
Pacer Advisors
238
Pacer Advisors
Pennsylvania
$263K +$261K +1,317 New
OAM
239
Oppenheimer Asset Management
New York
$256K +$20K +101 +9%
NG
240
Norden Group
Utah
$251K -$12.3K -62 -5%
XT
241
XTX Topco
Cayman Islands
$247K -$1.28M -6,480 -84%
Pathstone Holdings
242
Pathstone Holdings
New Jersey
$243K +$241K +1,218 New
M&T Bank
243
M&T Bank
New York
$242K +$240K +1,214 New
US Bancorp
244
US Bancorp
Minnesota
$242K -$4.95K -25 -2%
SFA
245
Sequoia Financial Advisors
Ohio
$240K +$238K +1,204 New
ATC
246
Argent Trust Co
Tennessee
$240K +$237K +1,200 New
Commonwealth Equity Services
247
Commonwealth Equity Services
Massachusetts
$237K +$15.8K +80 +7%
SC
248
Scotia Capital
Ontario, Canada
$232K +$230K +1,164 New
IA
249
Inspire Advisors
Idaho
$232K +$230K +1,161 New
CBU
250
CIBC Bancorp USA
Illinois
$226K +$224K +1,133 New
8 9
10
11 12

LGND Hedge Fund Activity: Q1 2026 in Review

357 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2026, worth a combined $4.15B — up 6.8% from $3.89B a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new LGND positions and 43 closed out — a net gain of 16 holders — while 133 added to existing stakes and 115 trimmed.

The largest buyer was Invesco, adding an estimated $60.8M. The largest seller was UBS AM, cutting an estimated $29.8M.

  • 357 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2026, up from 349 in Q4 2025.
  • Funds reported $4.15B of Ligand Pharmaceuticals stock for Q1 2026, up 6.8% quarter-over-quarter.
  • 59 funds opened new Ligand Pharmaceuticals positions in Q1 2026 and 43 closed out, a net change of +16 holders.
  • The largest Ligand Pharmaceuticals buyer in Q1 2026 was Invesco, an estimated $60.8M added.
  • The largest Ligand Pharmaceuticals seller in Q1 2026 was UBS AM, an estimated $29.8M sold.

Based on aggregated 13F filings for Q1 2026.